Clay Siegall: the face behind Seattle Genetics; a cancer treatment development company.

Clay Siegall: the face behind Seattle Genetics; a cancer treatment development company.

Seattle Genetics; a company that deals with antibody-based cancer therapies were co-founded by Clay Siegall in 1998. He is also the chairman of the Board of Governors, the president and CEO of the company. He has brought to work the building of cancer therapies that include ADCETRIS that was approved by the U.S Food and Drug Administration. Through his leadership, the company has engaged in capital-raising activities. From 1991 to 1997, Siegall worked at Bristol-Myers Squibb Pharmaceuticals Institute. He later worked at the National Cancer Institute and the National Institute of Health. Clay Siegall is an author. He has written over 70 publications and had 15 patents. He is also a board member of the following companies; Alder Biopharmaceuticals, Mirna Therapeutics and Fred Hutchinson Cancer Research Center. Siegall pursued an undergraduate degree in Zoology from the University of Maryland and later did his Ph.D. in Genetics at George Washington University.

Seattle Genetics has about 9000 employees and is ranked the largest biotech in Washington. It focuses on marketing and drug research. The company has produced a drug called ADCETRIS that treats Hodgkin lymphoma. This is a lymph cancer that can spread to another part of the body. Clay Siegall says that if the drug is approved, it will open a way for other drugs that the company has been researching on. He has a goal of ensuring that the drugs they produce get a more significant market instead of only focusing on drug innovation. He has proved this by bidding $ 2 billion to acquire drug marketing rights for a drug that was made by Immunomedics; a New Jersey-based company.

Antibody-drug conjugate is the drug that the company is putting many resources into. The drug aims antigens (protein, molecules that enable immunes system to produce antibodies). It kills cancer cells as well as not harming the healthy tissue. This is a definite innovation that reduces the collateral damage to healthy cells during chemo and radiation. Clay Siegall says that 4 of 11 drugs age a high success rate. The first drug is ADCETRIS. If approved, it will be the first drug to be used by oncologists in the treatment of cancer. The second drug is known as 33A. It aims at treated acute myeloid leukemia. The third is 22ME that targets bladder cancer and a wide range of urothelial carcinomas. The last drug is LIV1 that targets breast cancer.

Clay Siegall is an entrepreneur. He imitated and admired some of Art Levinson; founder of Genentech moves. He focused on how the company was structured and has since used it in Seattle Genetics. His mentor told him not to take no for an answer.